Stocks Overview

LAST PRICE
140.1100
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
130.5000/ 4
Ask / Lots
142.0000/ 1
Open / Previous Close
0.0000 / 140.1100
Day Range
---
52 Week Range
Low 93.2800
High 148.3699
Volume
3
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 137.67
Time	Volume	NBIX
09:32 ET	11859	138.155
09:34 ET	5673	139.39
09:36 ET	5084	139.88
09:38 ET	5100	140.265
09:39 ET	9973	139.805
09:41 ET	700	139.92
09:43 ET	15001	140.15
09:45 ET	7127	139.85
09:48 ET	1972	139.92
09:50 ET	2049	139.97
09:52 ET	3151	140.02
09:54 ET	7601	140.335
09:56 ET	3504	140.57
09:57 ET	4246	141.24
09:59 ET	13775	140.9272
10:01 ET	2459	141.665
10:03 ET	2678	140.995
10:06 ET	38235	140.65
10:08 ET	1749	140.83
10:10 ET	1863	141.02
10:12 ET	1931	140.675
10:14 ET	2262	140.55
10:15 ET	500	140.485
10:17 ET	1207	140.75
10:19 ET	750	141.02
10:21 ET	3987	140.96
10:24 ET	1885	140.655
10:26 ET	3927	140.665
10:28 ET	3166	140.79
10:30 ET	700	140.685
10:32 ET	1804	140.25
10:33 ET	1000	140.155
10:35 ET	1441	139.985
10:37 ET	1469	139.77
10:39 ET	1444	139.645
10:42 ET	1209	139.66
10:44 ET	2417	140.2
10:46 ET	300	139.605
10:48 ET	1000	139.73
10:50 ET	600	139.8
10:51 ET	400	139.82
10:53 ET	1200	139.665
10:55 ET	1007	139.56
10:57 ET	500	139.5
11:00 ET	741	139.66
11:02 ET	700	139.73
11:04 ET	2067	139.585
11:06 ET	600	139.73
11:08 ET	1615	139.73
11:09 ET	600	140.08
11:11 ET	1100	139.94
11:13 ET	907	139.935
11:15 ET	816	139.875
11:18 ET	700	139.885
11:20 ET	8594	140.07
11:22 ET	1474	140.04
11:24 ET	2995	139.965
11:26 ET	900	139.945
11:27 ET	1322	140.045
11:29 ET	800	139.88
11:31 ET	1200	139.75
11:33 ET	3017	139.87
11:36 ET	11700	139.47
11:38 ET	800	139.395
11:40 ET	1230	139.62
11:42 ET	655	139.42
11:44 ET	3007	139.41
11:45 ET	1225	139.47
11:47 ET	2624	139.4392
11:49 ET	803	139.37
11:51 ET	1416	139.285
11:54 ET	796	139.29
11:56 ET	1012	139.35
11:58 ET	1198	139.13
12:00 ET	600	139.2
12:02 ET	600	139.135
12:03 ET	400	139.095
12:05 ET	700	139.125
12:07 ET	1192	139.08
12:09 ET	1045	139.01
12:12 ET	200	139.01
12:14 ET	2822	139.11
12:16 ET	2578	139.02
12:18 ET	600	139.02
12:20 ET	1779	138.885
12:21 ET	500	138.795
12:23 ET	1000	138.825
12:25 ET	2772	138.775
12:27 ET	1500	138.645
12:30 ET	518	138.69
12:32 ET	500	138.53
12:34 ET	1300	138.515
12:36 ET	2528	138.71
12:38 ET	1100	138.85
12:39 ET	100	138.98
12:43 ET	400	138.985
12:45 ET	2524	139.12
12:48 ET	600	139.22
12:50 ET	300	139.25
12:52 ET	808	139.165
12:54 ET	1040	139.17
12:56 ET	400	139.1
12:57 ET	400	139.25
12:59 ET	1500	139.1
01:01 ET	100	139.185
01:03 ET	1000	138.96
01:06 ET	200	139.21
01:08 ET	100	139.29
01:10 ET	698	139.49
01:12 ET	300	139.479
01:14 ET	100	139.38
01:15 ET	400	139.44
01:17 ET	300	139.26
01:19 ET	100	139.38
01:21 ET	1007	139.5
01:24 ET	100	139.48
01:26 ET	151	139.48
01:28 ET	100	139.495
01:30 ET	500	139.59
01:33 ET	100	139.49
01:35 ET	400	139.35
01:42 ET	1420	139.16
01:44 ET	100	139.07
01:46 ET	100	139.175
01:50 ET	400	139.21
01:51 ET	600	139.26
01:57 ET	560	139.2
02:00 ET	100	139.265
02:02 ET	498	139.255
02:04 ET	100	139.35
02:06 ET	900	139.32
02:08 ET	917	139.535
02:11 ET	1300	139.62
02:13 ET	200	139.77
02:15 ET	100	139.77
02:18 ET	100	139.86
02:20 ET	300	139.87
02:22 ET	100	139.88
02:24 ET	400	139.845
02:26 ET	100	139.825
02:27 ET	777	139.69
02:29 ET	863	139.91
02:31 ET	547	140.01
02:33 ET	700	140.025
02:36 ET	1341	140.13
02:38 ET	100	140.09
02:40 ET	1030	140.175
02:42 ET	100	140.145
02:44 ET	406	140.07
02:47 ET	500	140.07
02:49 ET	335	140.085
02:51 ET	300	140.19
02:54 ET	200	140.19
02:56 ET	500	140.25
02:58 ET	705	140.175
03:00 ET	400	140.17
03:02 ET	300	140.13
03:03 ET	1619	140.335
03:05 ET	300	140.355
03:07 ET	676	140.42
03:09 ET	700	140.38
03:12 ET	620	140.37
03:14 ET	100	140.345
03:16 ET	200	140.35
03:18 ET	1000	140.07
03:20 ET	1100	140.19
03:21 ET	1500	140.09
03:23 ET	100	140.17
03:25 ET	300	140.08
03:27 ET	929	140.14
03:30 ET	700	140.115
03:32 ET	400	140.22
03:34 ET	500	140.25
03:36 ET	1706	140.2832
03:38 ET	200	140.285
03:39 ET	4879	140.08
03:41 ET	21026	139.655
03:43 ET	842	139.72
03:45 ET	200	139.67
03:48 ET	1721	139.705
03:50 ET	2206	139.95
03:52 ET	9006	140.055
03:54 ET	2066	140.02
03:56 ET	8685	140.025
03:57 ET	8278	140.2
03:59 ET	120855	140.11

Data delayed at least 15 minutes.

Yesterday
- DJ Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont, from 23 hours ago by Dow Jones
  23 hours ago by Dow Jones
- Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH, from 7:30AM ET on Monday Jul 01, 2024 by Dow Jones
  7:30AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 12, 2024
- DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
  1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
Jun 3, 2024
- Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones
  8:01AM ET on Monday Jun 03, 2024 by Dow Jones
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones
  7:35AM ET on Monday Jun 03, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesNBIX Neurocrine Biosciences Inc	14.1B	38.5x	+62.04%
United StatesMEDP Medpace Holdings Inc	12.6B	41.5x	+35.10%
United StatesUTHR United Therapeutics Corp	14.1B	15.1x	+8.22%
United StatesSRPT Sarepta Therapeutics Inc	14.8B	1,967.5x	---
United StatesBMRN Biomarin Pharmaceutical Inc	15.6B	77.7x	---
United StatesBGNE Beigene Ltd	15.7B	-19.1x	---
As of 2024-07-02

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Contact Information

Headquarters: 6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130
Phone: 858-617-7600
Fax: 858-617-7602

Executives

Non-Executive Independent Chairman of the Board: William Rastetter
Director: Kevin Gorman
Chief Financial Officer: Matthew Abernethy
Chief Human Resource Officer: Julie Cooke
Chief Scientific Officer: Jude Onyia

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$14.1B
Revenue (TTM)	$2.0B
Shares Outstanding	100.6M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.37
EPS	$3.64
Book Value	$22.61
P/E Ratio	38.5x
Price/Sales (TTM)	7.1
Price/Cash Flow (TTM)	36.0x
Operating Margin	23.43%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Charts

Recent News

Yesterday

DJ Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont, from 23 hours ago by Dow Jones

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH, from 7:30AM ET on Monday Jul 01, 2024 by Dow Jones

Jun 12, 2024

DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones

Jun 3, 2024

Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones

Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar